Know Cancer

forgot password

Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer

Phase 1
18 Years
Open (Enrolling)
Lung Cancer, Non-Small Cell

Thank you

Trial Information

Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer

Inclusion Criteria:

1. Male or female patient with completely resected (R0 resection), pathologically proven
stage IB, II or IIIA NSCLC. Patients are allowed to receive adjuvant platinum-based
chemotherapy for the treatment of the current NSCLC between surgery and enrolment.

2. Written informed consent for PRAME gene expression screening on resected tumor tissue
has been obtained from the patient prior to shipment of the sample for expression
testing, and written informed consent for the complete study participation has been
obtained before the performance of any other protocol specific procedure.

3. Patient is >= 18 years of age at the time of signature of the first informed consent

4. The patient's tumor shows expression of the PRAME gene.

5. The surgical technique for resection of the patient's tumor is anatomical, involving
at least a lobectomy or a sleeve lobectomy. The first ASCI administration will be
given, either within 12 weeks after surgery or within 8 weeks after day 1 of last
chemotherapy cycle and within 32 weeks after resection.

6. The patient is free of metastasis, as confirmed by a negative baseline computer
tomogram (CT scan) of the chest and upper abdomen as well as CT scan or magnetic
resonance imaging (MRI) of the brain. These tests are to be performed within 6 weeks
for the CT scan of the chest and upper abdomen and within 12 weeks for the brain CT
scan or MRI before first ASCI administration.

7. ECOG performance status of 0, 1 or 2.

8. Adequate bone-marrow reserve, renal, adrenal and hepatic function as assessed by
standard laboratory criteria

9. Female patients of non-childbearing potential may be enrolled in the study.
Non-childbearing potential is defined as current tubal-ligation, hysterectomy,
ovariectomy or post-menopause.

10. Female patient of childbearing potential may be enrolled in the study, if the

- has practiced adequate contraception for 30 days prior to study product
administration, and

- has a negative pregnancy test on the day of administration, and

- has agreed to continue adequate contraception during the entire treatment period
and for 2 months after completion of the study product administration series.

11. In the view of the investigator, the patient can and will comply with the
requirements of the protocol.

Exclusion Criteria:

1. The primary tumor was removed by segmentectomy or wedge resection.

2. The patient has received any anti-cancer specific treatment, including radiotherapy,
immunotherapy, chemotherapy or neo-adjuvant chemotherapy, except for the treatment of
previous malignancies allowed by the protocol.

3. The patient requires concomitant treatment (more than 7 consecutive days) with
systemic corticosteroids or any other immunosuppressive agents.

4. Use of any investigational or non-registered product (drug or vaccine, except
influenza vaccine in the context of H1N1 mass-vaccination) other than the study
product within the 30 days preceding the first dose of study product, or planned use
during the study period.

5. The patient has previous or concomitant malignancies at other sites, except
effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or
effectively treated malignancy that has been in remission for more than 3 years and
highly likely to have been cured.

6. History of allergic disease or reactions likely to be exacerbated by any component of
the study investigational product.

7. History of confirmed adrenal dysfunction.

8. The patient has an autoimmune disease such as, but not limited to, multiple
sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not

9. The patient has received a major organ allograft.

10. The patient is known to be Human Immunodeficiency Virus (HIV) -positive.

11. The patient has an uncontrolled bleeding disorder.

12. The patient has uncontrolled congestive heart failure or uncontrolled hypertension,
unstable heart disease (coronary artery disease or myocardial infarction) or
uncontrolled arrhythmia at the time of enrolment.

13. The patient needs home oxygenation.

14. The patient has psychiatric or addictive disorders that may compromise his/her
ability to give informed consent, or to comply with the trial procedures.

15. The patient has other concurrent severe medical problems, unrelated to the
malignancy, that would significantly limit full compliance with the study or expose
the patient to unacceptable risk.

16. For female patients: the patient is pregnant or lactating.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Occurrence of dose-limiting toxicities during study treatment

Outcome Time Frame:

During the study treatment period (up to 112 weeks, approximately 2 years and 2 months)

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Italy: Istituto superiore di sanità

Study ID:




Start Date:

July 2010

Completion Date:

January 2015

Related Keywords:

  • Lung Cancer, Non-Small Cell
  • Antigen-Specific Cancer Immunotherapeutic (ASCI)
  • PRAME-positive stage IB, II or IIIA Non-Small Cell Lung Cancer patients after complete surgical resection
  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



GSK Investigational Site Duluth, Minnesota  55805
GSK Investigational Site Pittsburgh, Pennsylvania  15213
GSK Investigational Site Seattle, Washington  98133
GSK Investigational Site Newark, Delaware  19713